rs225011 — DIO2

DIO2 rs225011 — An Intronic Variant in the Thyroid Hormone Activator Gene

DIO2 encodes type 2 iodothyronine deiodinase¹¹ type 2 iodothyronine deiodinase
The enzyme that catalyzes the outer-ring deiodination of thyroxine (T4), removing one iodine atom to produce the biologically active triiodothyronine (T3), the primary enzyme responsible for converting the thyroid prohormone T4 into the active T3 in peripheral tissues. DIO2 is especially important in the brain, pituitary, skeletal muscle, and brown adipose tissue, where up to 80% of intracellular T3 originates from local T4 conversion rather than direct uptake of serum T3. rs225011 is a common intronic variant in DIO2 — distinct from the well-studied Thr92Ala missense variant (rs225014)²² Thr92Ala missense variant (rs225014)
rs225014 is the coding DIO2 variant with the strongest clinical evidence, linked to impaired T4-to-T3 conversion efficiency and worse outcomes on levothyroxine monotherapy — that has been investigated in thyroid autoimmunity and metabolic disease, with modest and inconsistent findings.

DIO2 is a selenoprotein³³ selenoprotein
DIO2 contains a selenocysteine residue at its active site, coded by a UGA codon that is recoded by a SECIS element in the 3' UTR; selenium deficiency directly impairs DIO2 activity regardless of genotype that requires selenium as a cofactor. Its expression is regulated by TSH, cAMP signaling, and local thyroid hormone feedback. The gene sits on chromosome 14q24.2–q24.3, and rs225011 lies within intron 4 of the major transcript, approximately 2,577 base pairs upstream of exon 5 in transcript coordinates (NM_000793.6:c.223-2577A>T in HGVS notation on the minus-strand transcript).

The Mechanism

As an intronic variant, rs225011 does not change the DIO2 protein sequence. Its potential effects are regulatory — influencing how much DIO2 messenger RNA is produced, the efficiency of splicing of the DIO2 pre-mRNA, or serving as a tag SNP⁴⁴ tag SNP
A tag SNP is in linkage disequilibrium with a nearby causal variant in the same haplotype block; rs225011 may correlate with a functional regulatory element in intron 4 that hasn't been directly characterized marking a causal regulatory element not yet directly characterized. No eQTL (expression quantitative trait locus) data from GTEx or other resources has identified rs225011 as a significant predictor of DIO2 transcript levels in the tissues studied. The current interpretation is that rs225011 is a marker of a genomic region that influences thyroid disease risk through an incompletely understood mechanism.

The Evidence

The strongest reported association for rs225011 comes from a Swedish case-control study⁵⁵ Swedish case-control study
Shahida et al. European Thyroid Journal 2018 (PMID 30574458) of 712 Graves' disease patients and 1,183 sex-matched controls that examined seven DIO2 SNPs. rs225011 was nominally associated with Graves' disease (OR 1.18, 95% CI 1.01–1.37, p=0.036), but this association did not survive Bonferroni correction for the seven SNPs tested (threshold p<0.007). No DIO2 variant in that study was associated with Graves' ophthalmopathy, and rs225011 did not associate with FT3, FT4, or thyroid-stimulating hormone receptor antibody levels.

A Pima Indian study⁶⁶ Pima Indian study
Nair et al. Thyroid 2012 (PMID 22142372) of 1,311 subjects investigated five DIO2 variants including rs225011 for associations with early-onset type 2 diabetes and obesity. rs225011 showed nominal associations with T2DM (p=0.01–0.04) in a case-control analysis, but none of the DIO2 variant associations — including rs225011 — survived correction for multiple testing. Similarly, a study of four DIO2 SNPs including rs225011 in 149 Jordanian hypothyroid patients on levothyroxine found no association between rs225011 genotype and levothyroxine dose requirements or metabolic parameters.

The mechanistic context is important: the [Thr92Ala DIO2 variant (rs225014) | The coding DIO2 variant with the strongest evidence; see the DIO2 rs225014 entry for the full evidence base] has been shown by Jo et al. 2019⁷⁷ Jo et al. 2019
J Clin Invest, PMID 30352046 to cause endoplasmic reticulum stress and localized hypothyroidism in the brain, providing a compelling model for how DIO2 dysfunction leads to tissue-level T3 insufficiency despite normal serum thyroid panels. Whether rs225011 participates in the same pathway — perhaps by modulating DIO2 expression or interacting with rs225014 on a haplotype — is an open question that current evidence cannot resolve.

Practical Actions

Given the limited and inconsistent evidence for rs225011 itself, the actionable implications for C-allele carriers focus on the selenium dependency of DIO2 (regardless of genotype, DIO2 activity is contingent on adequate selenium), awareness of thyroid autoimmunity risk factors, and appropriate monitoring. The variant does not currently warrant changes to thyroid hormone replacement therapy — that decision is better guided by the DIO2 rs225014 (Thr92Ala) result⁸⁸ DIO2 rs225014 (Thr92Ala) result
The coding DIO2 variant with clinical-grade evidence for altered treatment response and by clinical symptoms.

Interactions

rs225011 has been genotyped alongside rs225014 (Thr92Ala) and rs12885300 in multiple DIO2 studies, and these variants are located in moderate linkage disequilibrium within the DIO2 gene on chromosome 14. If you carry both rs225011 (CC or CT) and the Thr92Ala variant (rs225014 CC or CT), the combined haplotype may tag a more complete picture of DIO2 regulatory and functional impairment than either variant alone, though no published compound analysis specifically examines this pair's joint effects.

DIO2 activity intersects with selenium nutrition: even in the absence of genetic variants, selenium deficiency (common in European populations with low dietary intake) reduces selenoprotein synthesis and impairs T4-to-T3 conversion across all tissues. Selenium status is therefore a modifiable factor that complements genetic assessment of thyroid hormone metabolism.